AMELY

Across TCGA pan-cancer cohorts, AMELY RNA is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AMELY data layer compared with 1 for mutation status and 8 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AMELY RNA is associated with better overall survival. In most high-consensus cancer types, elevated AMELY expression acts as an unfavorable survival marker, although some lineages such as BLCA and PRAD show a favorable association.

BLCA, KIRC, and TGCT are the cancer types where AMELY RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.728	0.574	.010	48	view →
KIRC	DFS	Tertile	All	0.127	0.865	<.001	18	view →
TGCT	DFS	Quartile	All	0.747	0.875	.022	12	view →
LIHC	DFS	Tertile	All	0.418	0.580	.015	12	view →
STAD	OS	Tertile	All	0.266	0.456	.040	3	view →
SARC	OS	Tertile	All	0.657	0.877	.044	3	view →
PRAD	OS	Quartile	All	1.000	0.968	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AMELY–BLCA (OS)

Open the BLCA breakdown →